Ovid Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
Consolidated Statement of Changes in Stockholders’ Equity
| (in thousands, except shares) · ConvertiblePreferred Stock · Common Stock · AdditionalPaid-In Capital · AccumulatedOtherComprehensive Loss · Accumulated Deficit · Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||||||
| Balance, December 31, 2024 | 1,250 | $— | 71,009,866 | $71 | $372,489 | $(35) | $(304,299) | $68,226 | ||||
| Conversion of Series A convertible preferred stock to common stock | (1,250) | — | 1,250,000 | 1 | (1) | — | — | — | ||||
| Conversion of Series B convertible preferred stock to common stock | — | — | 57,722,000 | 58 | 49,251 | — | — | 49,309 | ||||
| Issuance of Series A warrants | — | — | — | — | 13,802 | — | — | 13,802 | ||||
| Issuance of Series B warrants | — | — | — | — | 17,700 | — | — | 17,700 | ||||
| Expenses related to the sale of Series B preferred stock and Series A and Series B warrants | — | — | — | — | (5,694) | — | — | (5,694) | ||||
| Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan | — | — | 202,487 | — | 91 | — | — | 91 | ||||
| Stock-based compensation expense | — | — | — | — | 4,807 | — | — | 4,807 | ||||
| Other comprehensive loss | — | — | — | — | — | (167) | — | (167) | ||||
| Net loss | — | — | — | — | — | — | (17,414) | (17,414) | ||||
| Balance, December 31, 2025 | — | $— | 130,184,353 | $130 | $452,445 | $(202) | $(321,713) | $130,660 | ||||
| (in thousands, except shares) | ConvertiblePreferred Stock | Common Stock | AdditionalPaid-In Capital | AccumulatedOtherComprehensive Income (Loss) | Accumulated Deficit | Total | ||||||
| Shares · Amount · Shares · Amount | ||||||||||||
| Balance, December 31, 2023 | 1,250 | $— | 70,691,992 | $71 | $365,591 | $1 | $(277,866) | $87,797 | ||||
| Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan | — | — | 317,874 | — | 622 | — | — | 622 | ||||
| Stock-based compensation expense | — | — | — | — | 6,276 | — | — | 6,276 | ||||
| Other comprehensive loss | — | — | — | — | — | (36) | — | (36) | ||||
| Net loss | — | — | — | — | — | — | (26,433) | (26,433) | ||||
| Balance, December 31, 2024 | 1,250 | $— | 71,009,866 | $71 | $372,489 | $(35) | $(304,299) | $68,226 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.